Segment Information (Tables)

3 Months Ended

Mar. 31, 2024

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the condensed consolidated financial statements.


	Net Sales to External Customers				Operating Earnings
	Three Months Ended March 31				Three Months Ended March 31
(in millions)	2024		2023		2024		2023
Established Pharmaceutical Products	$	1,226	$	1,189	$	267	$	300
Nutritional Products	2,068		1,967		377		380
Diagnostic Products	2,214		2,688		474		651
Medical Devices	4,453		3,900		1,360		1,078
Total Reportable Segments	9,961		9,744		2,478		2,409
Other	3		3
Net sales	$	9,964	$	9,747
Corporate functions and benefit plan costs					(66)		(77)
Net interest expense					(61)		(52)
Share-based compensation (a)					(304)		(281)
Amortization of intangible assets					(472)		(491)
Other, net (b)					(139)		54
Earnings before taxes					$	1,436	$	1,562

______________________________________


(a)			Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)			Other, net for the three months ended March 31, 2024 and March 31, 2023 includes charges related to restructuring actions. Other, net for the three months ended March 31, 2024 also includes integration costs associated with the acquisition of CSI and $38 million related to various investment impairments.